CiteULike  View Full Text   View/Add Comment  Download reader    
Yu-tuan Wu,Xin Li,Lin-jie Lu,Lu Gan,Wei Dai,Yan-ling Shi,Vishnu Prasad Adhikari,Kai-nan Wu,Ling-quan Kong.Journal of Biomedical Research,2018,32(3):191-197
Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients
Received:June 14, 2017  Revised:January 06, 2018
DOI10.7555/JBR.32.20170059
Keywordsbreast cancer, neoadjuvant chemotherapy, hormone receptors, Ki67
Grant Program
                          
AuthorInstitution
Yu-tuan Wu Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing , China
Xin Li Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing , China
Lin-jie Lu Department of Thyroid and Breast Surgery, Liuzhou People¨s Hospital, Liuzhou, Guangxi , China
Lu Gan Department of Oncology and Radiology, the First Affiliated Hospital of Chongqing Medical University, Chongqing , China
Wei Dai Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing , China
Yan-ling Shi Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing , China
Vishnu Prasad Adhikari Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing , China
Kai-nan Wu Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing , China
Ling-quan Kong Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing , China
Hits: 48
Download times: 32
      
Abstract
      This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor (ER), progesterone receptor (PR) and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry. Differences between specimens made through preoperative core needle biopsy and excised tissue biopsy were observed. The positive rates of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy were 65.3% and 63.2%, 51.0% and 42.6%, 65.6% and 43.4%, respectively. The expression of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy had no statistically significant difference. However, after neoadjuvant chemotherapy, the discordance rates of ER, PR and Ki67 were 15.2% (79/521), 26.9% (140/520) and 44.8% (225/502), respectively. The ER, PR and Ki67 status changed from positive to negative in 7.5% (39/521), 13.3% (69/520) and 21.1% (106/502) of the patients, whereas ER, PR and Ki67 status changed from negative to positive in 7.7% (40/521), 13.6% (71/520) and 23.7% (119/502) of the patients, respectively. These results showed that the status of some biomarkers changes after neoadjuvant chemotherapy and biomarker status needs to be reexamined to optimize adjuvant systemic therapy and better prognosis assessment.
Close